ACT News 209.00 06/16/2014 04:22:32 Actavis Inc (ACT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actavis Inc (ACT) 209.00 $ACT

Actavis Strives To Reduce Borrowing Costs
at Investor's Business Daily - Fri Jun 13, 5:48PM CDT
Generic, branded and biosimilar drugmaker Actavis (ACT) may be well-known among investors as a company that has used large acquisitions as one method to boost its earnings and sales sharply. Yet less attention perhaps has been paid to its savvy...

Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.

Actavis Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Forest Laboratories Senior Notes
PR Newswire - Thu Jun 12, 5:16PM CDT
Actavis plc (NYSE: ACT) today announced that Forest Laboratories, Inc. (NYSE: FRX) has received valid consents (the "Requisite Consents" from holders of a majority in aggregate principal amount of each series of Forest's securities listed in the table below (the "FRX Notes" to the elimination of Forest's contractual registration rights obligations with respect to each series of FRX Notes (the "Proposed Amendments" (collectively, the "Consent Solicitations" . As consideration for the Requisite Consents, Actavis will fully, unconditionally and irrevocably guarantee (each, a "ACT Guarantee" and, together, the "ACT Guarantees" each series of FRX Notes, subject to the closing of Actavis' pending acquisition (the "Acquisition" of Forest and certain other customary conditions. The terms and conditions of the Consent Solicitations are described in the Offering Memorandum/Consent Solicitation Statement, dated May 22, 2014 (as may be amended or supplemented from time to time, the "Consent Solicitations Statement" .

Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
Business Wire - Thu Jun 12, 4:00PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it had received valid consents (the "Requisite Consents" from holders of a majority in aggregate principal amount of each series of its securities listed in the table below (the "FRX Notes" to the elimination of Forest's contractual registration rights obligations with respect to each series of FRX Notes (the "Proposed Amendments" (collectively, the "Consent Solicitations" . As consideration for the Requisite Consents, Actavis plc (NYSE:ACT) will fully, unconditionally and irrevocably guarantee (each, a "ACT Guarantee" and, together, the "ACT Guarantees" each series of FRX Notes, subject to the closing of Actavis' pending acquisition (the "Acquisition" of Forest and certain other customary conditions. The terms and conditions of the Consent Solicitations are described in the Offering Memorandum/Consent Solicitation Statement, dated May 22, 2014 (as may be amended or supplemented from time to time, the "Consent Solicitations Statement" .

VIVUS Files Lawsuit Against Actavis for Infringement of Qsymia Patents
Marketwire - Thu Jun 12, 3:33PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis.

Worldwide IV Iron Drugs Industry Analysis and 2018 Forecasts New Research Study Available at MarketReportsOnline.com
PRWeb - Thu Jun 12, 4:03AM CDT
Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron.

Today's Top Performers In Health Care
at The Street - Wed Jun 11, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Actavis to close USD3.7bn senior unsecured notes on 19 June 2014
M2 - Wed Jun 11, 4:51AM CDT
Pharmaceutical company Actavis (NYSE:ACT) said on Tuesday that its Actavis Funding SCS indirect subsidiary has priced its total aggregate offering of USD3.7bn senior unsecured notes 19 June 2014.

Actavis, BitAuto Among Leading World Stocks In Bases
at Investor's Business Daily - Tue Jun 10, 5:50PM CDT
Six of the 10 stocks listed on the Top World Stocks list in Tuesday's IBD are pecking away at new highs. Some are still in buying range after clearing bases. Four others are building bases. One minor catch: They are all late-stage patterns. Late...

Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.

Lannett In Buying Range After Breakout From Cup Base
at Investor's Business Daily - Tue Jun 10, 3:35PM CDT
Generic-drug maker Lannett (LCI) is in buying range following a breakout from a cup-without-handle base. The stock is within the 5% buy area after succeeding Monday in its third try to clear the 46.61 buy point. The previous attempts last Thursday...

Fitch Rates New Actavis Bonds 'BBB-'; Outlook Stable
Business Wire - Tue Jun 10, 9:55AM CDT
Fitch Ratings has assigned a 'BBB-' rating to new senior unsecured bonds to be issued by an indirect subsidiary of Actavis plc (NYSE: ACT). Fitch has also assigned a 'BBB-' Issuer Default Rating (IDR) to Actavis Funding SCS, the issuer of the bonds, and Warner Chilcott Limited. ACT's IDR is 'BBB-', with a Stable Outlook. A full list of ratings for ACT follows at the end of this release.

Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.

Actavis Finalizes Agreement Related to Asacol® HD Patent Challenge Litigation
PR Newswire - Mon Jun 09, 4:54PM CDT
Actavis plc (NYSE: ACT) today announced that it has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol® HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013.

Why I Like Actavis Stock
Mohsin Saeed, The Motley Fool - Motley Fool - Mon Jun 09, 1:12PM CDT
Investments in small capitalization biotechnology companies are fraught with risks. Most bio-techs rely on a single or a few trial candidates to determine their entire valuations. With little or no revenues, the downside to these stocks is immense. A...

Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations" to eliminate existing registration rights obligations with respect to its outstanding debt securities listed in the table below (the "FRX Notes" in exchange for the offer by Actavis plc (NYSE: ACT) to guarantee (the "ACT Guarantees" each of the FRX Notes. The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.

Actavis Extends Expiration Time of Offer to Guarantee Certain Forest Laboratories Senior Notes in Connection with Forest Consent Solicitations
PR Newswire - Mon Jun 09, 7:00AM CDT
Actavis plc (NYSE: ACT) (the "Company" today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes" of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations" . The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.

Several IBD 50 Names Set Up In Stock Picker's Market
at Investor's Business Daily - Fri Jun 06, 4:58PM CDT
A nascent market uptrend, confirmed by the Nasdaq and S&P 500 on May 27, is looking pretty good. Distribution days, or higher-volume declines, have been nonexistent so far and growth stocks overall are holding up well. The IBD 50 is essentially flat...

The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market

More Stock Leaders Emerge From More Industry Groups
at Investor's Business Daily - Thu Jun 05, 5:03PM CDT
The set of 16 charts on IBD Stock Spotlight's computer-run screen are showing two promising new trends. The first trend: Since the Nasdaq's May 27 confirmation of a new market uptrend, more stocks are hitting proper buy points, while others are...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 121

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 159

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 125

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 6

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 189

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading

Top 5 Most Recently Viewed Articles

GRAX Honored as Cybersecurity Innovator by BostInno Awards

Updated Category News Views 66

GRAX Recognized as a Leader in Cybersecurity GRAX, Inc., well-known for its innovation in Salesforce data management and protection, has recently earned an esteemed recognition as a 2024 Fire honoree in cybersecurity from BostInno. This award celebrates companies that are driving innovation in the Boston area, emphasizing GRAX's role as a pioneer in data security....

Continue Reading
i2Cool and Marubeni Join Forces for Revolutionary Cooling Tech

Updated Category News Views 286

i2Cool and Marubeni Forge Strategic Partnership i2Cool, a pioneering company in the realm of electricity-free cooling technology, has established a significant global partnership with Marubeni, a prominent trading company from Japan. This collaboration is designed to facilitate the widespread adoption of electricity-free cooling technologies, concentrating particularly on...

Continue Reading
Jasper Therapeutics Upcoming Investor Conferencs - September 2024

Updated Category News Views 82

Jasper Therapeutics to Showcase Innovations at September Events Jasper Therapeutics, Inc. (NASDAQ: JSPR), a leader in biotechnology, is preparing for a series of investor conferences this September. The company is particularly excited to discuss briquilimab, an innovative antibody therapy designed to treat c-Kit (CD117) driven mast cell diseases, including chronic...

Continue Reading
Tech Sector Thrives as Meta Drives Nasdaq-100 to New Heights

Updated Category News Views 303

Tech Sector Soars with New Nasdaq-100 Records The Nasdaq-100 has reached an unprecedented high of 22,191.37, highlighting the unyielding strength of tech stocks. The renowned Invesco QQQ Trust (NASDAQ: QQQ) has also achieved a 52-week peak, reaching $540, demonstrating the energetic rally across the technology market. Meta Platforms Inc's Remarkable Performance Meta...

Continue Reading
Millicom Advances Infrastructure Sale and Special Dividend Plans

Updated Category News Views 207

Millicom Announces Infrastructure Deal Progress Millicom International Cellular S.A. (NASDAQ: TIGO) has made significant strides in its transaction with SBA Communications. The company recently revealed the partial closing of its sale involving LATI International S.A., the holding company for its mobile passive infrastructure assets in Central America. This deal has...

Continue Reading